HEPATITIS C VIRUS AMONG PREGNANT WOMEN PEOPLE LIVING WITH HIV AIDS ATTENDING CLINIC (A Case Study Of Unth Itukuozalla)

 

Table Of Contents


  • Title pageCertificationDedicationAcknowledgementTable of contentList of tableAbstractCHAPTER ONE1.1 INTRODUCTION1.2 ObjectivesCHAPTER TWO2.1 MODE OF TRANSMISSION AND RISK FACTORS
  • 2.2Pathogenesis and incubation period2.3 Epidemiology2.4 Signs and symptoms2.5 Diagnosis2.6 Prevention and control2.7 Treatment2.8 Hepatitis C virus and pregnancy2.9 Hepatitis C virus and HIVCHAPTER THREE3.1 MATERIAL3.2 Study population3.3 Sample collection3.4 MethodCHAPTER FOUR4.1 RESULTSCHAPTER FIVE5.1 DISCUSSION5.2 Conclusion5.3 RecommendationReferences

Project Abstract

A total of 50 blood (30 pregnant and 20 HIV) samples were obtained from pregnant women and PLWHA attending clinic at UNTH Ituku-ozalla. Samples were screened for hepatitis c viral infection using the rapid one step hepatitis C virus test strip. Two (6.66%) pregnant women were positive and four (20%) HIV patients were positive for Hepatitis C, giving an overall prevalence rate of (26.7%). The infection was the same in male (3) and in female (3). Those aged 23-34 years recorded a higher prevalence of (20%) than those in the age group 19-23. This higher prevalence of hepatitis C suggests that pregnant women and PLWHA may be at risk of hepatitis due to hepatitis C virus. Therefore routine screening of pregnant women and PLWHA should be instituted for early diagnosis and management of cases.

Project Overview

1.1INTRODUCTION
Hepatitis C infection is an infection of the liver caused by the hepatitis C virus (HCV). HCV is one of several viruses that can cause hepatitis. ‘Hepatitis’ means inflammation of the liver(Ryan and Ray,2004).It is unrelated to the other common hepatitis viruses (for example, hepatitis A or hepatitis B). HCV is a member of thehepacivirus genus in the familyFlaviviridae. There are at least six distinctly different strains of the virus which have different genetic profiles (genotypes). In the U. S., genotype 1 is the most common form of HCV. Even within a single genotype there may be some variations (genotype 1a and 1b, for example). Genotyping is important to guide treatment because some viral genotype respond better to therapy than others (Wilkins et al. 2009).
According to Hepatitis C NSW (2010), here are some of the things that can happen once the body contract hepatitis C.
The body may deal with hepatitis C of its own accord and you may never get sick.About 25% of all people who contract hepatitis C will clear the infection (although this happen less commonly in people with HIV). For a range of reasons, hepatitis C infection is eradicated from the body in these people, usually within 12 months of having been infected.
Hepatitis C may remain present in the body. About three quarters of people who contract hepatitis C will be chronically infected. This means that they have detectable hepatitis C virus (measured by a PCR test) in their blood for a period of longer than twelve months. People in this group may be at risk of developing liver problems over time.
The genetic diversity of HCV is one reason that it has been difficult to develop an effective vaccine since the vaccine must protect against all genotypes. It is difficult for the human immune system to eliminate HCV from the body, and infection with HCV usually becomes chronic. Over decades, chronic infection with HCV damages the liver and can cause liver failure. Up to 85% of newly-infected people fail to eliminate the virus and become chronically infected. Infection is most commonly detected among people who are 40 to 60 years of age, reflecting the high rates of infection in the 1970s and 1980s. There are 8,000 to 10,000 deaths each year in the U.S. related to HCV infection. HCV infection is the leading cause of liver transplantation in the U.S and is a risk factor for liver cancer.
Most of the signs and symptoms of HCV infection relate to the liver. Less commonly, HCV infection causes conditions outside of the liver. Symptoms are generally mild and vague, including a decreased appetite, fatigue, nausea, fever. Headache, muscle or joint pains, and weigh loss.Hepatitis C after many years
becomes the primary cause of cirrhosis and liver cancer. About 10–30% of people develop cirrhosis over 30 years (Meisel, et al. 1995).
HCV infection can cause the body to produce unusual antibodies called ‘cryoglobulins’. These cryoglobulins cause inflammation of the arteries (vasculitis) which may damage the skin, joints, and kidneys. In addition, these patients may develop Raynaud’s phenomenon in which the fingers and toes turn color (white, then purple, then red) and become painful at cold temperatures(Iannuzzella, and Vaglio, 2010).
Two skin conditions, lichen planus and porphyria cutaneatarda, have been associated with chronic infection with HCV. HCV also is associated with B-cell lymphoma, a cancer of the lymph system.
Doctors use various tests to determine if a person has hepatitis C. One type of test measures antibodies in the blood, indicating that a person been exposed to HCV; the two most common antibody tests are called ELISA and RIBA. Viral load tests measure how much HCV genetic material is present in the blood; the two most common viral load tests are called PCR and bDNA.
Who to test for hepatitis c virus
According to MMWR (1998) Persons who ever injected illegal drugs,
Persons who were ever on chronic (long-term) hemodialysis;
Persons with persistently abnormal alanine aminotransferase level
Persons who were notified that they received blood from a donor who later tested positive for HCV infection;
Persons who received a transfusion of blood or blood components and organ transplant before July 1992; and
Healthcare, emergency medical and public safety workers after needle sticks, or mucosal exposures to HCV-positive blood
Children born to HCV-positive women.
1.2 OBJECTIVES
i. To determine the prevalence of hepatitis C virus in pregnant women attending ante-natal in UNTH Ituku-ozalla
ii. To determine the age distribution where the infection occurs most
iii. To determine the prevalence of hepatitis virus in people living with HIV and AIDS attending UNTH Ituku-ozalla.

Blazingprojects Mobile App

📚 Over 50,000 Project Materials
📱 100% Offline: No internet needed
📝 Over 98 Departments
🔍 Software coding and Machine construction
🎓 Postgraduate/Undergraduate Research works
📥 Instant Whatsapp/Email Delivery

Blazingprojects App

Related Research

Pharmacy. 2 min read

Evaluation of nanocarrier-based drug delivery systems for targeted cancer therapy: f...

What This Project Is About A plain-language overview of the topic and what the project investigates. The Problem It Addresses Explains a gap in how cancer drug...

BP
Blazingprojects
Read more →
Pharmacy. 2 min read

Development and optimization of a nanoparticle-based targeted drug delivery system f...

What This Project Is About A plain-language overview of the topic and what the project investigates. The Problem It Addresses Current cancer treatments can har...

BP
Blazingprojects
Read more →
Pharmacy. 4 min read

Development and optimization of a nanoparticle-based targeted drug delivery system f...

What This Project Is About A simple exploration of how tiny particles can carry cancer drugs inside the body to target tumors more precisely, using natural mate...

BP
Blazingprojects
Read more →
Pharmacy. 3 min read

1) Development and formulation of a novel nanoemulsion-based topical delivery system...

What This Project Is About A final year project that explores advanced drug delivery and pharmacology topics. It covers making a tiny nanoemulsion cream to deli...

BP
Blazingprojects
Read more →
Pharmacy. 3 min read

Development and validation of a novel transdermal patch formulation for sustained re...

What This Project Is About A straightforward exploration of a skin-friendly patch that releases a chosen anti-inflammatory drug slowly over time. The project lo...

BP
Blazingprojects
Read more →
Pharmacy. 3 min read

Development and optimization of a novel in-silico ADMET screening workflow for repur...

What This Project Is About A simple, AI-assisted project exploring how existing FDA-approved drugs can be repurposed to fight drug-resistant bacteria using comp...

BP
Blazingprojects
Read more →
Pharmacy. 3 min read

Evaluation of a novel nanoparticle-based delivery system for targeted anticancer the...

What This Project Is About The project explores a new nanoparticle system designed to deliver a natural product–based anticancer compound directly to cancer c...

BP
Blazingprojects
Read more →
Pharmacy. 4 min read

Development and pharmacokinetic evaluation of a novel nanoemulsion-based topical for...

What This Project Is About The project explores a special oil-in-water tiny droplet system (a nanoemulsion) that helps medicines dissolve better on the skin and...

BP
Blazingprojects
Read more →
Pharmacy. 3 min read

Development of a novel nano-formulation for targeted delivery of anticancer agents i...

What This Project Is About A plain-language overview of the topic and what the project investigates. It looks at designing tiny carriers (nanoparticles) to deli...

BP
Blazingprojects
Read more →
WhatsApp Click here to chat with us